HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit.

Abstract
Background: The world, and Italy on the front lines, has experienced a major medical emergency due to the novel coronavirus outbreak. Cancer patients are one of the potentially most vulnerable cohorts of people, but data about their management are still few. Patients and Methods: In this monocentric retrospective study we included all SARS-CoV-2 oncological patients accepted, between March 27th and April 19th 2020, at the Onco-COVID Unit at San Luigi Gonzaga Hospital, one of the few Italian oncological-COVID wards. Data were obtained from medical records. Results: Eighteen cancer patients with COVID-19 were included. The mean (±SD) age of patients was 67 ± 14 years, 89% were men. Seven (39%) developed infection in communities and 11 (61%) during hospitalization. Lung cancer was the most frequent type of cancer (10, 56%). Seven patients (39%) were symptomatic for COVID-19 at the time of diagnosis and symptoms began 2 (±2) days before. The most common were shortness of breath and diarrhea. Fever was present in 5 patients (28%). Among the 11 asymptomatic patients, 8 (73%) became symptomatic during the hospitalization (mean time of symptoms onset 4 days ±4). Six patients (33%) were on active anti-tumor treatment: 2 (33%) received anti-tumor therapy within 2 weeks before the infection diagnosis and 2 (33%) continued oncological treatment after SARS-CoV-2 positivity. Eight (44%) patients died within a mean of 12 days (±8) from the infection diagnosis. Conclusions: Our series confirms the high mortality among cancer patients with COVID-19. The presence of asymptomatic cases evidences that typical symptoms and fever are not the only parameters to suspect the infection. The Onco-Covid unit suggests the importance of a tailored and holistic approach, even in this difficult situation.
AuthorsMaria Lucia Reale, Paolo Bironzo, Valentina Bertaglia, Erica Palesandro, Gianmarco Leone, Fabrizio Tabbò, Maristella Bungaro, Marco Audisio, Annapaola Mariniello, Simonetta G Rapetti, Rosario F Di Stefano, Elisa Artusio, Enrica Capelletto, Paola Sperone, Adriana Boccuzzi, Marco Calandri, Alberto Perboni, Umberto Malapelle, Francesco Passiglia, Silvia Novello
JournalFrontiers in oncology (Front Oncol) Vol. 10 Pg. 1722 ( 2020) ISSN: 2234-943X [Print] Switzerland
PMID32974210 (Publication Type: Journal Article)
CopyrightCopyright © 2020 Reale, Bironzo, Bertaglia, Palesandro, Leone, Tabbò, Bungaro, Audisio, Mariniello, Rapetti, Di Stefano, Artusio, Capelletto, Sperone, Boccuzzi, Calandri, Perboni, Malapelle, Passiglia and Novello.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: